CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.
Munters Group AB posted the largest decline among large stocks during the session, plunging 11.0%, followed by Camurus AB shares, which declined 9.8%. Shares of Lifco AB Series B fell 5.8%.
The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...
The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...
In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...
The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...
Medpage Today on MSN20h
Acromegaly Injectable Rejected; Nobel Prize Winner Dies; Obesity Doubles in KidsSchally, PhD-- who won a Nobel Prize for discovering the hormones used by the brain to control growth, reproduction, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback